ALUMIS Business Summary

Alumis Inc. (ALMS) is a late-stage clinical biopharmaceutical company specializing in the development of precision therapies for immune-mediated diseases. The company’s business model centers on leveraging its proprietary data analytics platform to identify and advance highly selective small molecules, primarily generating value through its drug development pipeline and potential future commercialization or licensing agreements. Its primary business segments are categorized by its therapeutic candidates: envudeucitinib (formerly ESK-001), a selective allosteric TYK2 inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis and Phase 2b for systemic lupus erythematosus; A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory diseases; and lonigutamab, an anti-IGF-1R therapy for thyroid eye disease. Alumis competes directly with major pharmaceutical players and biotech firms such as Bristol Myers Squibb (Sotyktu), Takeda (TAK-279), and Aclaris Therapeutics, positioning itself as a next-generation leader aiming for superior efficacy and safety profiles over first-generation inhibitors. The leadership team is anchored by President, CEO, and Chairman Martin Babler, who previously served as CEO of Principia Biopharma until its $3.7 billion acquisition by Sanofi. The executive suite includes Chief Financial Officer John Schroer, Chief Development Officer Mark Bradley, and Chief Medical Officer Jörn Drappa, many of whom bring significant pedigree from industry giants like Genentech and Principia. The company was incubated by Foresite Labs and is backed by a robust roster of institutional investors, including Foresite Capital, Samsara BioCapital, and venBio Partners. The board of directors features prominent industry figures such as Srinivas Akkaraju and James Tananbaum, reflecting a high level of strategic oversight from the venture capital and clinical development sectors.